Nav: Home

Study reveals key inner control mechanism of cell's 'smart glue'

February 26, 2018

Researchers at St. Jude Children's Research Hospital have discovered that a protein critical to a process called liquid-liquid phase separation within the cell undergoes internal changes in conformation that are key to its function.

The protein, nucleophosmin, is a kind of "smart glue" in a structure called the nucleolus inside the cell's nucleus. In the nucleolus, nucleophosmin helps organize and regulate the construction of ribosomes--the biological machines that assemble proteins using their RNA genetic code as a guide.

Nucleophosmin is critical to the liquid-like structure of the nucleolus called a membrane-less organelle. That is because unlike cell structures like the nucleus, the nucleolus is not enclosed in membranes. Instead, the nucleolus and other such organelles are something like the colorful undulating blobs in lava lamps--dynamically forming, shifting and fusing.

The paper describing the "self-interaction" of nucleophosmin was published in the February 26 issue of the journal Nature Communications, by a research team led by Richard Kriwacki, Ph.D., a member of the St. Jude Department of Structural Biology.

In earlier studies, Kriwacki and colleagues had discovered how nucleophosmin binds to proteins and RNA to foster phase separation, as well as ribosomes' assembly. However, their studies of nucleophosmin were yielding results hinting that its "heterotypic" reactions--those with proteins other than itself and RNA--did not fully explain how part of the molecule called the intrinsically disordered region functioned.

"The results were not fitting our previous model for how this domain was mediating phase separation," Kriwacki said. "This led us to an alternative hypothesis that this region was undergoing conformational changes and interacting with itself."

In further experiments, first author Diana Mitrea, Ph.D., a staff scientist in Kriwacki's laboratory, explored the mysterious mechanism.

The experiments point to how the intrinsically disordered region undergoes changes as ribosomes are assembled and the makeup of the nucleolus changes. The changes were to increase homotypic interactions, or within the nucleophosmin molecule itself. The research also revealed how nucleophosmin interacts with another protein called SURF6. Scientists discovered SURF6 acts as a partner to nucleophosmin in creating and maintaining the loose scaffolding that holds the fluid nucleolus together.

"Once we realized it was happening, this self-interaction didn't seem so surprising, because other such disordered proteins we had studied had been shown to undergo phase separation through such homotypic reactions," Kriwacki said.

The experiments revealed important new details of the mechanism by which the smart glue nucleophosmin changes its internal conformation as the liquid-like nucleolus facilitates ribosome assembly. At an early stage of the process, its primary job is to shepherd RNA and proteins to assemble ribosomes. But as the glue molecule hands off its cargo as ribosomes form, the glue molecule adjusts itself homotypically to interact with other glue molecules.

This cross-linking of nucleophosmin proteins constitutes a kind of buffering, in which nucleophosmin helps maintain the liquid consistency of the nucleolus. In this buffering, the homotypic mechanism competes with nucleophosmin's heterotypic mechanisms by which it attaches to RNA and proteins in helping assemble ribosomes.

The insights into nucleophosmin's role in the nucleolus will offer broader insights into the mechanism of phase separation in other membrane-less organelles in the cell, Kriwacki said.

The research could also have important clinical implications, for example in understanding the molecular basis of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. St. Jude molecular biologist and chair of the Department of Cell and Molecular Biology, J. Paul Taylor, M.D., Ph.D., has identified an abnormal building block of membrane-less organelles called stress granules that underlies ALS. Kriwacki and his colleagues are working to understand how that abnormality relates to nucleophosmin's function in the nucleolus. Drs. Taylor and Kriwacki previously reported that a different abnormality associated with ALS, expression of so-called toxic dipeptide repeats, affects nucleophosmin's nucleolar function and inhibits ribosome assembly.

Also, mutations in nucleophosmin are the most frequent molecular abnormalities in adult acute myeloid leukemia. In future studies, Kriwacki and colleagues plan to explore how the abnormal nucleophosmin drives the leukemia.
-end-
The paper's other authors are Jaclyn Cika, Amanda Nourse, Aaron Phillips, Cheon-Gil Park of St. Jude; Christopher Stanley of Oak Ridge National Laboratory; and Paulo Onuchic, Priya Banerjee and Ashok Deniz, all of The Scripps Research Institute.

The research was sponsored by grants (5RO1GM115634, RO1 GM066833) from the National Institutes of Health; (CA21765) from the National Cancer Institute, part of the NIH; and ALSAC, the fundraising and awareness organization of St. Jude.

St. Jude Children's Research Hospital

Related Leukemia Articles:

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.
Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.
Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.
The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.
Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.
Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.
Finding second hits to knock out leukemia
Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks.
Understanding the emergence of leukemia
Acute T-cell lymphoblastic leukemia is a rare type of blood cancer that affects mostly children.
New treatment approach for leukemia
An international research team led by researchers from Vetmeduni Vienna have made an important discovery that could lead to a better understanding of lymphocytic leukemia.
More Leukemia News and Leukemia Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.